Patent Application Attorney Docket No. PC11026AJAK

ondence is being deposited with the United States Postal Service as firstclass mail in an envelope addressedto: Hon. Commissioner for Patents, Washington, D.C. 20231 on this 21st day of February, 2002. I hereby certify that

Deanna L. Miller (Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Stephanie K. Hall, et al

Examiner: To be assigned APPLICATION NO.: 10/032,242

Group Art Unit: 1645 FILING DATE: December 21, 2001

RECFIVED TITLE: Methods and Reagents for Detecting Increased

Risk of Developing An Inflammatory Disorder

MAR 0 5 2002 Hon. Commissioner for Patents **TECH CENTER 1600/2900**

Washington, D.C. 20231


Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).



A prompt and favorage poince is earnestly solicited.

Date: FEBRUARY 21, 2002

Respectfully submitted,

enifer A. Kispert

Attorney for Applicant(s)

Reg. No. 40,049

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5747

MAR 0 1 2002

INFORMATION DISCLOSURE CITATION 10/032,242 SERIAL NO. ATTY DOCKET NO. PC11026AJAK **APPLICANT** Stephanie K. Hall, et al (Use several sheets if necessary) 1645 **GROUP** FILING DATE December 21, 2001 U.S. PATENT DOCUMENTS FILING DATE IF APPROPRIATE CLASS SUBCLASS NAME DATE DOCUMENT NUMBER **EXAMINER** INITIAL RECEIVE **MAR 0 5** 2002 FOREIGN PATENT DOCUMENTS TECH CENTER 1600/2900 TRANSLATION SUBCLASS COUNTRY DATE DOCUMENT NUMBER YES NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) A. C. Issekutz, et al., Immunology, Volume 88, pages 569-576, 1996, "Treatment of Established Adjuvant Arthritis in Rats With Monoclonal Antibody to CD18 and Very Late Activation Antigen-4 Integrins Suppresses Neutrophil and T-lymphocyte Migration to the Joints and Improves Clinical Disease". M. P. Bevilacqua, et al., Science, Vol. 243, pages 1160-1165, March 3, 1989, "Endothelial Leukocyte Adhesion Molecule 1: An Inducible Receptor for Neutrophils Related to Complement Regulatory Proteins and Lectins". Z. Guan, et al., The Journal of Biological Chemistry, Vol. 273, No. 44, Issue of October 30, pages 28670-28676, 1998, "Interleukin-1 ß-induced Cyclooxygenase-2 Expression Requires Activation of Both c-Jun NH₂-terminal Kinase and p38 MAPK Signal Pathways in Rat Renal Mesangial Cells" C. R. Flannery, et al., Matrix Biology, Volume 18, pages 225-237, 1999, "Effects of Culture Conditions and Exposure to Catabolic Stimulators (IL-1 and Retinoic Acid) on the Expression of Matrix Metalloproteinases (MMPs) and Disintegrin Metalloproteinases (ADAMs) by Articular Cartilage Chondrocytes". E. M. El-Omar, et al., Nature, Vol. 404, pages 398-402, March 23, 2000, "Interleukin-1 Polymorphisms Associated With Increased Risk of Gastric Cancer". F. Pociot, et al., European Journal of Clinical Investigation, Vol. 22, pages 396-402, 1992, "A Taql Polymorphism in the Human Interleukin-1 ß secretion in vitro". C. Zheng, et al., British Journal of Haematology, Volume 109, pages 39-45, 2000, "Interleukin 6, Tumour Necrosis Factor α , Interleukin 1β and Interleukin 1 Receptor Anatgonist Promoter or Coding Gene Polymorphisms in Multiple Myeloma". M. Takamatsu, et al., The American Journal of Gastroenterology, Vol. 95, No. 5, pages 1305-1311, 2000, "Genetic Polymorphisms of Interleukin-1 β in Association With the Development of Alcoholic Liver Disease in Japanese Patients". D. Huang, et al., Journal of Neuroimmunology, Vol. 81, pages 76-81, 1998, "Polymorphisms in IL-1 β and IL-1 Receptor Antagonist Genes are Associated With Myasthenia Gravis". S. Santtila, et al., Scand. J. Immunol., Volume 47, pages 195-198, 1998, "Presence of the IL-1RA Allele 2 (IL1RN*2) is Associated With Enhanced IL-1β Production In Vitro". U. T. Hacker, et al., European Journal of Clinical Investigation, Volume 28, pages 214-219, 1998, "Inflammatory Bowel Disease: No Association Between Allele Combinations of the Interleukin (IL) I β and IL-I Receptor Antagonist Gene Polymorphisms". S. Cookson, et al., Vol. 30, No. 4, pages 851-856, 1999, "Frequency and Nature of Cytokine Gene Polymorphisms in Type 1 Autoimmune Hepatitis". E. Sharma, et al., The Journal of Biological Chemistry, Vol. 270, No. 1, Issue of January 6, pages 49-53, 1995, "A Neuronal Protein Tyrosine Phosphatase Induced by Nerve Growth Factor".

	611	P	E	3
(N	AAR O	1	2002	85 Ju

INFORMAT	TION DISCLOSURE CONTION	ATTY. DOCK	ET NO. PC11026AJAK	SERIAL NO.	10/032,242			
(Use s	FRANK PROPERTY OF TRANKS	APPLICANT	Stephanie K. Hall, et al					
-		FILING DATE	December 21, 2001	GROUP	1645			
	M. Ogata, et al., The Journal of Biolog Characterization of a Novel Receptor	gical Chemistry, Vo -type Protein Tyros	ol. 270, No. 5, Issue of February 3, sine Phosphatase Expressed Pred	pp. 2337-2343, 199 ominantly in the Bra	5, cDNA Cloning and in*."			
	W. Hendriks, et al., Biochem. J., Volume 305, pages 499-504, 1995, A Novel Receptor-Type Protein Tyrosine Phosphatase With a Single Catalytic Domain is Specifically Expressed in Mouse Brain."							
	G. Daum, et al., Analytical Biochemistry, Volume 211, pages 50-54, 1993, "A General Peptide Substrate for Protein Tyrosine Phosphatases".							
	K. W. Harder, et al., Biochem. J., Volume 298, pages 395-401, 1994, "Characterization and Kinetic Analysis of the Intracellular Domain of Human Protein Tyrosine Phosphatase β (HPTP β) Using Synthetic Phosphopeptides".							
EXAMINER		С	DATE CONSIDERED					
ŀ								

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with

Conforms with FORM PTO-FB-A820

next communication to applicant.

INFORMATION DISCLOSURE

RECEIVED

MAR 0 5 2002

TECH CENTER 1600/2900